Tag Archives: JPM

Are You Ready For RESI JPM? Time To Check Out The Program Guide

4 Jan

By Nono Hu, Director of Marketing, LSN

JPM week is almost upon us, and at Life Science Nation, we’re making the final preparations for RESI San Francisco. It’s our largest event of the year; if you want to join over a thousand life science executives and investors for targeted one-on-one meetings, you’ve got 5 more days to sign up. In the meantime, please check out the RESI Program Guide below to see all our RESI Innovators, sponsors, exhibitors and speakers. With attendees from all over the world coming to RESI to make new connections and continue compelling dialogues, RESI San Francisco is the most focused event next week for early stage companies and investors. We’ll look forward to seeing you all face to face next week.

Orphan Drug Investors Discuss the Current Rare Disease Environment during RESI@JPM

21 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

A large number of early stage biotechs are pursuing orphan disease indications.  This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

14 Dec

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital

RESI @ JPM Partnering Launches Monday – See Who’s Attending

7 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wpThe annual JP Morgan healthcare week will soon be upon us and we’re excited to be bringing the RESI conference back to the Bay for a high energy day of partnering, panels and networking. The RESI conference always hosts a wide variety of investment firms, strategic partners and startups, but each year’s San Francisco event is unmatched in the volume and diversity of global players in the mix.

On the investor/strategic partner side, you’ll find everyone from angel groups, venture philanthropy and endowments, venture capital and private equity, family offices, mid-size and big pharma. As for startups, RESI accommodates biotech/pharma (therapeutics), medtech (devices and diagnostics) and healthcare IT/digital health. Have a look at the some of the folks you can meet.

Confirmed Investors and Strategic Partners

Click to See Full List…

Confirmed Companies

Click to See Full List…

RESI JPM 2018: Agenda Announced

30 Nov

By Jessica Yang, Investor Research Analyst, LSN

Biotech and medtech industry executives are drawing up their itineraries for January’s healthcare conference week in San Francisco, and over a thousand attendees are expected to join Life Science Nation for our Redefining Early Stage Investments (RESI) Conference in San Francisco on January 9th!

LSN would now like to announce the agenda for RESI San Francisco. Our event will provide a full day of investor panels and workshops devoted to early-stage life science investment topics. RESI features four tracks of content, including the RESI Asia-North America track, which offers attendees the chance to hear directly from investors and strategic partners from across the Pacific who are seeking North American innovation. These panels will be a must-see for any fundraising entrepreneur in the life science sector.

In addition to RESI’s recurring core sector panels Early Stage Therapeutics, Medical Device Investors, Diagnostics and Healthcare IT, RESI San Francisco will also feature the Big Data & Healthcare Panel. The big data space has increasingly become exciting with its potential to transform healthcare through its cross-correlation to broad applications. In addition, LSN will be bringing back the highly popular panel on Genomics. Genomics is becoming a major technology for life science investment, and the panel will provide the opportunity to learn about the kinds of genomic-related breakthrough that investors are looking to back, and the challenges of investing in the genomics field. Be sure to register now for these tremendous opportunities to learn how investors think about your space.

RESI JPM 2018 Early Bird Registration Is Open

26 Oct

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On January 9th, 2018, the Redefining Early Stage Investments (RESI) Conference will join the JPM fray again for our largest event yet in San Francisco.

In the last two RESI JPM conferences, we had to close registrations two weeks early as we’d reached capacity. In RESI JPM 2018, LSN is expecting to bring together 500+ fundraising CEOs and 500+ early stage investors from around the globe and host over 2000 scheduled and ad hoc meetings in one high energy day.

RESI JPM will offer early stage companies and investors an opportunity to get the most out of the wild week when the biotech and medtech world gathers by the Bay. Register early to secure your partnering meetings with investors and strategic partners that are a fit.

“Know your investors and live your business plan” – BioWorld Highlights RESI @ JPM

19 Jan

By Lucy Parkinson, Director of Research, LSN

As RESI attracts increasing media attention, BioWorld have provided some highlights and analysis on RESI’s content. This roundup focuses on two of RESI’s investor panels: Biotech Angels and Tales From The Road. Between these two sessions, RESI attendees caught a high-level view inside an early stage life science deal from both sides. On one side of the table, angel investors explore how they hunt for deals and work with startups after investment. On the other side, successful CEOs share their stories of finding and vetting investors who are a fit for their companies. You can read more at BioWorld: http://www.bioworld.com/content/know-your-investors-and-live-your-business-plan

%d bloggers like this: